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A proposal for a directive on patients’ rights in 
cross-border healthcare—defined as healthcare 
provided or prescribed in a member state other 
than that of affiliation1—has been approved by the 
European Parliament and will be formally adopted 
by the Council of Health Ministers in February. 
The Directive on the Application of Patients’ Rights 
in Cross-Border Healthcare (http://ec.europa.eu/
health/ph_overview/co_operation/healthcare/
docs/COM_en.pdf) could provide greater clarity 
on the rules governing patients travelling abroad 
to receive treatment. Moreover it could affect indi-
vidual member states’ national health systems.
We should be concerned about how this issue 
is addressed. First, European citizens show a 
growing interest in travelling abroad to receive 
treatment.2  3 A recent survey in all member states 
found that 53% overall expressed a willing-
ness to seek treatment in another country of the 
Eu ropean Union (EU).2 This finding was supported 
by surveys among German patients enrolled with 
a nationwide health insurance fund. In 2003 
only 7% had obtained non-urgent treatment in 
another EU country, but by 2008 the proportion 
had increased to 40%.3 Second, any solution may 
have implications for how domestic health systems 
are run. In this paper we describe who is affected 
by the directive, review its proposals,1 and review 
the process that has given rise to the directive. We 
discuss its most contentious issues and examine its 
potential implications for patients, health profes-
sionals, and policy makers.
Who is affected by the directive
Mobile patients include temporary visitors abroad, 
people living in border regions, people sent abroad 
by their home systems, those seeking treatment 
on their own initiative, and those retiring to other 
countries4 (box 1). The directive covers all patients 
travelling abroad to receive treatment in another 
member state, except those currently covered by 
existing social security legislation (such as tour-
ists, pensioners and cross-border workers).5 This 
would include, for example, someone seeking 
a specialist consultation elsewhere in the EU, 
who would be re imbursed to the amount that it 
would cost in their home country. Additionally, 
all patients treated abroad will benefit, directly or 
indirectly, from the directive’s provision of infor-
mation on treatment abroad and the establishment 
of national contact points to provide it.
The content of the proposal and its 
legislative process
In July 2008 the European Commission first adopted 
the proposal for a directive on the application of 
patients rights in cross-border healthcare.11 It sought 
to establish a clear legal framework within the Euro-
pean Union by resolving ambiguities about the 
mechanisms involved in providing such care and 
establishing systems in which member states can 
c ooperate to resolve outstanding issues.
The right to healthcare in another EU member 
state was established in 1971,12 with the regulations 
updated most recently in 20045 and implemented in 
May 2010.13 The scope of the legislation was limited 
to people in need of treatment while temporarily 
abroad and those receiving advance authorisation 
from their own health payer.6 However, a series of 
rulings by the European Court of Justice14-19 has 
expanded these provisions, progressively escalating 
the range of care that can be obtained without seek-
ing advance authorisation—but with the sp ecifics 
of rulings on individual, and often quite unusual, 
cases leaving several areas unclear (box 2). The 
directive is intended to resolve these issues, provid-
ing clarity for patients, healthcare professionals, 
and policy makers.
The directive applies to all healthcare provision 
that patients are entitled to at home, regardless 
of how it is organised, financed, and delivered. It 
gives EU citizens the right to obtain from abroad any 
care not requiring a hospital stay without advance 
authorisation. However, where inpatient care or cer-
tain specialised investigations are involved, member 
states may create a system of prior authorisation to 
enable them to manage patient flows and avoid 
threats to the financial and operational sustainabil-
ity of their health systems. In both cases, patients 
will only be entitled to reimbursement under this 
directive up to what would have been paid for if 
the care was provided at home. National contact 
points will be established to provide patients with 
information on rights and procedures. The direc-
tive also makes provision for mutual recognition 
of prescriptions written abroad and establishes a 
system of European Reference Networks for highly 
specialised care, as well as enhanced cooperation 
on e-health and on health technology assessment.11
The progress of this directive has been arduous 
(see box 3 on bmj.com for timeline22-27). European 
legislation is proposed by the European  Commission 
for agreement by the Council of Ministers (rep-
resenting national governments) and the European 
 Parliament. After an extensive consultation process, 
the commission’s Directorate General for health and 
consumers finally published its proposals on 2 July 
2008. A compromise between the Parliament and the 
Council was reached in December 2010.
Challenges to ensuring quality and safety, 
benefits, and information needs
We focus on three issues that have proved most 
challenging in creating a legal framework 
for cross-border care: quality, benefits, and 
 information needs.
HEALTH SYSTEMS PERSPECTIVES
Cross-border healthcare in Europe: 
clarifying patients’ rights 
The adoption of a new directive on cross-border healthcare in the European Union could bring 
clarity for patients, health professionals, and policy makers, as well as raise the awareness of how 
healthcare differs between EU member states, say Helena Legido-Quigley and colleagues
This paper is part of an occasional series prepared in 
conjunction with the European Observatory on Health 
Systems and Policies (www.healthobservatory.eu)
bmj.com Previous articles in the Health Systems Perspectives series
 ЖMaintaining the competence of Europe’s workforce (BMJ 2010;341:c4687)
 ЖCan user charges make health care more efficient? (BMJ 2010;341:c3759)
 ЖStoking the antibiotic pipeline (BMJ 2010;340:c2115)
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Assuring quality and safety
The directive reaffirms that member states retain 
responsibility for providing safe and high quality 
care on their territory and that cross border health-
care should be provided according to their own 
standards of quality and safety. This requires, first, 
that effective mechanisms for quality of care exist 
in each country. At a system level these include 
mechanisms to ensure the quality of drugs (reg-
istration and licensing), technologies including 
devices and medical procedures (health technol-
ogy assessment), and the workforce (training and 
continuing education of health professionals). 
At a clinical level they include the creation and 
implementation of practice guidelines, monitor-
ing systems, and quality assurance systems. Sec-
ond, member states will have to address issues 
that are specific to cross-border care, in particular 
where follow-up visits are needed.9  28 At present, 
approaches to healthcare quality and patient 
safety vary widely in their nature, scope, and cov-
erage and the existing Europe-wide initiatives are 
largely driven by voluntary professional groupings.
Benefits
Even though health professionals in different 
countries read the same medical literature, man-
agement of similar conditions still varies consider-
ably between (and even within) countries. These 
variations are apparent in the mix of staff involved 
(such as whether a task is performed by a doctor or 
a nurse), the extent of investigation, and the mode 
and setting of treatment.29 This creates consider-
able scope for confusion when a payer is asked 
to reimburse a package of care that may be quite 
different from what they expected— if the greatly 
varying cl assifications used even allow for such a 
comparison. For example, someone with an acute 
stroke may be treated much more aggressively in 
one country than in another.30
Information needs
One of the most important provisions of the 
di rective is the supply of good information for 
cross-border patients on the care they receive—
information that will benefit not only those who 
seek healthcare abroad but also those who choose 
to remain in their own country. The national con-
tact points will have to provide information on 
healthcare providers, including assessment, 
registration status, and restrictions on practice, 
patients’ rights, procedures for reimbursement, 
and complaint and redress mechanisms. Each 
healthcare pr ovider must supply patients with 
information on availability, quality, and safety of 
care, clear invoices, and information on prices. 
This process will ultimately increase the transpar-
ency of healthcare systems and is likely to stimu-
late the improvement of care. However, it will 
pose many challenges, especially in decentralised 
health systems—including the reorganised NHS, 
where it will create substantial additional respon-
sibilities for the proposed general practice commis-
sioning consortiums.21 Another important aspect 
relates to communication between providers. This 
is addressed through provisions on e-health and 
by giving patients the right to access their medi-
cal record in both their home state and where they 
receive tr eatment.
Controversial issues
The most controversial issue, ever since health-
care was first discussed at European level, has 
been the principle of subsidiarity. Proposals have 
been judged by politicians in terms of the extent 
to which they interfered with the right of member 
states to organise and deliver their own system 
of healthcare, as set out in article 168 of the Lis-
bon Treaty. In part this reflects the origins of the 
legislation in policies on advancing the internal 
market rather than improving health. From an 
internal market perspective, healthcare is a serv-
ice like any other and Europe’s citizens should be 
Box 1 | Types of patients moving within Europe4
Temporary visitors abroad
Travellers abroad who fall ill in another member state are entitled to medical treatment in the country 
they are visiting on presentation of a European Health Insurance Card (which replaced the E111 form). An 
example is the large seasonal influx of tourists to the Veneto region (Italy), where the local health authority 
had to create special health services to cater for the tourist season.6
People retiring to other countries
Many older people from northern Europe retire to southern Europe. They include many British pensioners 
retiring to Spain who register with the Spanish system and are then treated the same way as Spanish 
citizens (using the E121 form).7
People in border regions
Most cross-border healthcare takes place in border regions where collaborations have served to rationalise 
services, as many borders traverse sparsely populated areas, dividing communities that share common 
languages and cultures. One of the oldest collaborations in Europe is that in the Euregio Meuse-Rhine region, 
dating from 1976, where three countries (Holland, Germany, and Belgium), with three national legal systems 
and four different cultures, collaborate in more than 15 cross-border healthcare projects.8
People sent abroad by their home systems
In some cases purchasers establish procedures to allow patients to go abroad for healthcare. This normally 
happens to respond to waiting lists, overcome a shortage of domestic provision, or to obtain highly 
specialised services, particularly in smaller member states where the populations are insufficient to justify 
local provision. For example, a bilateral agreement between Malta and the UK allows Maltese patients to 
obtain specialised hospital treatment in London.9
People going abroad on their own initiative
These people typically travel abroad to receive healthcare that is cheaper (such as spas, cosmetic surgery, 
and dental treatment), faster, or considered to be of better quality than in their home country. Patients 
may also seek interventions that are prohibited at home, such as abortions or fertility treatment, with the 
term “fertility tourism” coined to describe travelling to countries where donor anonymity is guaranteed for 
sperm and egg donations.10
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able to obtain it freely 
from anywhere within 
the EU. National gov-
ernments, concerned 
about costs of treat-
ment abroad and the 
sustainability of their 
domestic health sys-
tems, have taken a dif-
ferent view. They have 
also been concerned 
about exacerbating 
inequalities, because 
the proposal is likely 
to disproportionately 
benefit wealthy and 
well informed patients.
The most controver-
sial issues during the 
negotiations between 
the council and parlia-
ment have been: prior 
authorisation, prepay-
ment, treatment of 
rare diseases, the defi-
nition of quality and 
safety standards, and 
e-health.
Governments, through the Council of Ministers, 
have sought to develop criteria that increase their 
scope to refuse prior authorisation. For example, 
although they have tried to limit the scope of the 
commission to gather information on quality of 
care in other countries, they have also argued 
that concerns about the quality of care elsewhere 
should be grounds for refusal. The parliament and 
the commission, on the other hand, have argued 
that the council’s proposed criteria, which were 
non-exhaustive, were so vague as to increase legal 
uncertainty. Although the parliament was, in prin-
ciple, against any prior authorisation, it accepted it 
as long as the criteria for refusal are objective and 
limited.
The European Parliament also differed from 
the council on payment, proposing that the home 
country should have paid in advance rather than 
citizens having to pay upfront. One potential 
mechanism, rejected by the council, was the crea-
tion of a voucher system. Instead it was agreed that 
member states must at least ensure that patients are 
reimbursed as rapidly as possible unless they can 
opt for alternative mechanisms that already exist 
under social security legislation (regulation (EC) no 
883/2004). Another point of disagreement related 
to Europeans affected by rare diseases, which some 
estimates suggest may 
apply to as many as 
25 million individu-
als.31 The parliament 
argued that affected 
patients should have 
been entitled uncon-
ditionally to obtain 
healthcare abroad 
(including medicines) 
without any form of 
previous authorisation 
and be reimbursed 
even if the treatment 
in question was not 
among the benefits of 
their home system—a 
view contested by the 
council.
The commission 
and the parliament 
wanted to impose on 
member states the 
obligation to define 
clear quality and 
safety standards. The 
council opposed this, 
proposing as a com-
promise provisions to encourage member states 
to do so, including the possibility of refusing prior 
authorisation in cases of serious and concrete con-
cerns about the quality and safety of care provided 
by a specific provider in another member state.
Finally, on e-health, the council has challenged 
provisions that would allow the commission to pro-
mote interoperability, an action not well received by 
either the commission or parliament.
Remaining controversies
Most problems have been resolved during the 
negotiations, but certain areas are likely to remain 
unresolved. First, some issues have been left out of 
the current version of the directive1 such as e-health 
services and standards of quality, which will not 
be addressed at EU level. Measures on these and 
issues such as rare diseases will be left to coop-
eration among member states, with the directive 
simply pointing to the possibilities offered by regu-
lation (EC) no 883/2004 for referral of patients for 
diagnosis and treatments which are not available 
in the home member state.32
Other areas could generate confusion when 
implemented—for example, the process of prior 
authorisation; the mechanisms for calculating 
costs of cross-border healthcare for each member 
state; and what is included in the reimbursement 
of a treatment. These areas could prove difficult 
for member states from an administrative point 
of view (particularly establishing the cost of treat-
ment). Moreover some of the concepts included in 
the directive (such as what is a medically justifiable 
time limit) could be difficult to define in practice 
and thus give rise to different interpretations. Ulti-
mately, the directive could introduce inequalities if 
there are differences in how member states decide 
to reimburse the costs of cross-border healthcare, 
with some only providing the minimum requested 
and others deciding to reimburse related costs, 
such as accommodation, travel costs, or extra costs 
incurred by people with disabilities.
What does the directive mean for patients, 
health professionals and policy makers?
The benefits for patients
The volume of cross-border care in Europe will 
probably continue to increase, not least due to 
greater awareness among patients and those advis-
ing them. The current situation is far from satisfac-
tory and a framework that brings greater clarity to 
an often confusing situation is clearly welcomed. 
In particular, the directive codifies and clarifies a 
growing body of case law for which applicability 
to a particular case is often uncertain. It will also 
extend the opportunities to obtain care abroad, 
although the extent to which it succeeds will only 
become clear once experience has been gathered 
of how the directive works in practice . European 
reference networks will be of particular interest to 
patients with rare diseases, offering them access 
to specialised care that might not have been pos-
sible otherwise, although the ease of accessing it 
remains uncertain.
Implications for policy makers
Policy makers will also benefit from the greater cer-
tainty about legal and financial aspects of cross-
border care.33  34 The directive will offer them new 
options to address common problems such as 
waiting lists, underused facilities, and the ability 
to manage rare diseases. It should lead to improved 
mechanisms for sharing data, improving quality of 
care, greater compatibility of patient records, and 
the ability to prescribe across borders.21  35
Implications for healthcare providers and 
professionals
Healthcare providers will need to understand 
much better the diversity of treatment pathways 
that exist in Europe for common conditions, as 
well as becoming familiar with regulations, enti-
Box 2 | Examples of the role of European Court 
rulings
• Kohll and Decker (1998)14—Two citizens from 
Luxemburg, Mr Kohll and Mr Decker, requested 
reimbursement for orthodontic treatment and 
the purchase of spectacles acquired in Germany 
and Belgium, respectively. The European Court 
considered that Luxembourg’s statutory health 
insurance rules had created an impediment 
to the free movement of goods and services 
and established that individuals could obtain 
certain goods and medical services provided 
outside hospital and be reimbursed by their 
health funder without prior authorisation.20
• The Watts Case (2006)18—In 2002, Yvonne 
Watts, a 72 year old living in the UK, was 
diagnosed with osteoarthritis. Facing a one 
year wait for hip replacement at her local NHS 
hospital, and being refused treatment abroad, 
she decided, on her own initiative, to seek 
treatment in France.10 The European Court 
confirmed that patients facing “undue delay” at 
home, defined by their clinical condition rather 
than potentially arbitrary targets, may travel 
to another member state for treatment and 
expect to receive reimbursement for the cost of 
treatment because of “undue delay.”18
• European Commission versus French Republic 
(2010)19— French insurers required anyone 
going abroad for diagnosis or treatment 
that needed “major medical equipment” to 
seek prior authorisation if they were to be 
reimbursed. The European Court confirmed 
that prior authorisation was justified given the 
risk to the health system in terms of cost and 
distribution of major capital investments. 21
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tlements, and mechanisms for redress and com-
pensation.33 The directive will provide a solid 
legal basis for greater co-operation across borders 
(including e-health solutions), which will be of 
particular value in sparsely populated areas.
Conclusion
That the organisation of cross-border care in 
Europe creates many problems has long been 
agreed, but achieving a solution has been diffi-
cult. Whether the directive offers such a solution 
remains to be seen. A tension persists between the 
Council of Ministers, which tends to see itself as a 
guardian of national health systems, and the Euro-
pean Parliament, which tends to see itself as the 
voice of Europe’s citizens (and potential patients), 
although many different views are held within 
both. The directive was approved in the European 
Parliament by an overwhelming majority on 19 
January. The council will adopt it formally in Feb-
ruary and the legislation will enter into force by 
the spring. Member states will have 30 months to 
transpose it into national law, so it should there-
fore become fully effective by 2013. This directive 
will at least bring a degree of clarity to this often 
confusing landscape but its success or failure will 
only become apparent once it is clear how it has 
been implemented. 
Helena Legido-Quigley research fellow , London School of 
Hygiene and Tropical Medicine, London, UK
Ilaria Passarani senior policy officerscientific researcher , 
Cecile Knai lecturer in European health policy , London School 
of Hygiene and Tropical Medicine, London, UK
Reinhard Busse professor of health care management, 
Technische Universität, Berlin, Germany
Willy Palm dissemination development officer, European 
Observatory on Health Systems and Policies, Brussels, Belgium
Matthias Wismar senior health policy analyst, European 
Observatory on Health Systems and Policies, Brussels, Belgium
Martin McKee professor of European public health, London 
School of Hygiene and Tropical Medicine, London, UK 
helena.legido-quigley@lshtm.ac.uk
This article was published online on 17 January 2011 and has 
since been updated to reflect the approval of the directive by 
the European Parliament on 19 January.
The European Observatory on Health Systems and Policies 
is about to publish a new volume on Cross-border health 
care in the European Union. Mapping and analyzing practices 
and policies (Wismar M, Palm W, Figueras J, Ernst K, van 
Ginneken E, eds). 
The study will be available at www.euro.who.int/en/home/
projects/observatory/publications/studies
Contributors: HL-Q, IP, CK, and MM drafted the article. All authors 
revised subsequent drafts. MM is guarantor. All authors have 
worked in EU funded projects on patient mobility and cross-
border healthcare and have published extensively on this subject. 
This article arose from discussions with EU decision makers, 
including participation in workshops and other meetings on this 
topic. HL-Q, MM, MW, and WP contributed to the commission’s 
impact assessment of an earlier draft of the directive. The 
main sources of information were the official documents of the 
European Institutions.
Competing interests: All authors have completed the Unified 
Competing Interest form at www.icmje.org/coi_disclosure.
pdf (available on request from the corresponding author) 
and declare: HL-Q, MM, RB, MW, and WP had financial 
support from the European Community (Health and 
Consumer Protection Directorate General; grant agreement 
2006WHO05) and through the FP7 Cooperation Work 
Programme: Health (contract number 242058; contract 
acronym EUCBCC) for the submitted work; no financial 
relationships with any organisations that might have an 
interest in the submitted work in the previous three years; 
no other relationships or activities that could appear to have 
influenced the submitted work.
Provenance and peer review: Commissioned, externally peer 
reviewed.
1 European Parliament. Recommendations for second 
reading on the council position at first reading with a view 
to the adoption of a directive of the European Parliament 
and of the council on the application of patients’ rights in 
cross-border healthcare 11038/2010 – C7 0266/2010 – 
2008/0142(COD)). 2010. www.europarl.europa.eu/sides/
getDoc.do?type=REPORT&mode=XML&reference=A7-
2010-0307&language=EN.
2 European Commission. Flash Eurobarometer. Cross-border 
health services in the EU: analytical report. The Gallup 
Organization, 2007.
3 Techniker Krankenkasse. TK Europe Survey 2009: German 
patients en route to Europe. Corporate Development 
Department (UE) and the Scientific Institute for Benefit and 
Efficiency in Healthcare (WINEG), 2009.
4 Legido-Quigley H, Glinos I, Baeten R, McKee M. Patient 
mobility in the European Union. BMJ  2007;334:188-90.
5 European Parliament and Council of the European Union. 
Regulation (EC) no 883/2004 of the European Parliament 
and of the council of 29 April 2004 on the coordination of 
social security systems: Official Journal of the European 
Union L 166, Official Journal L 149, 30.4.2004. 2004.
6 Bertinato L, Busse R, Fahy N, Legido-Quigley H, Mckee 
M, Palm W, et al. Policy brief: cross-border health care 
in Europe. World Health Organization on behalf of the 
European Observatory on Health Systems and Policies, 
2005: 28.
7 Legido-Quigley H. Experiencing health care: the accounts 
of British pensioners migrating to Spain. London School of 
Hygiene and Tropical Medicine, 2010.
8 Glinos IA, Baeten R. A literature review of cross-border 
patient mobility in the European Union. Observatoire social 
europeen, asbl, 2006: 114.
9 Legido-Quigley H, McKee M, Nolte E, Glinos IA. Assuring 
the Quality of Health Care in the European Union: A case 
for action. World Health Organization on behalf of the 
European Observatory on Health Systems and Policies, 
2008
10 Legido-Quigley H, McKee M, Nolte E. Quality of care, patient 
orientation, information to patients and professionals. 
London School of Hygiene and Tropical Medicine, 2005: 
291.
11 Commission of the European Communities. Proposal for a 
directive of the European Parliament and the council on the 
application of patients’ rights in cross-border healthcare 
COM (2008) 414 final. 2008.
12 European Parliament and Council of the European Union. 
Council regulation (EEC) no 1408/71 of 14 June 1971 on 
the application of social security schemes to employed 
persons and their families moving within the community: 
Official Journal L 149, 05.07.1971. 1971.
13 European Parliament and Council of the European Union. 
Regulation EC 987/2009 of 16 September 2009 laying 
down the procedure for implementing regulation (EC) no 
883/2004 on the coordination of social security systems, 
OJ L 284 of 30 October 2009: Official Journal of the 
European Union. 2009.
14 European Court of Justice. Case C-158/96 [Raymond Kohll v 
Union des Caisses de Maladie], 28 April 1998.
15 European Court of Justice. Case C-120/95 [Nicolas Decker v 
Caisse de Maladie des Employes Prives], 28 April 1998.
16 European Court of Justice. Case C-157/99, [Geraets-Smits 
v Stichting Ziekenfonds VGZ and H.T.M. Peerbooms v 
Stichting CZ Groep Zorgverzekeringen], 12 July 2001.
17 European Court of Justice. Case C-368/98, [Vanbraekel 
and Others v Alliance nationale des mutualités 
chrétiennes (ANMC)], 12 July 2001.
18 European Court of Justice. Case C-372/04, [Yvonne Watts v 
Bedford Primary Care Trust], 16 May 2006.
19 European Court of Justice. Case C-512/08 [European 
Commission v French Republic], 5 October 2010.
20 Palm W, Nickless J. Access to healthcare in the European 
Union—the consequences of the Kohll and Decker 
judgements. Eurohealth 2001;7:13-5.
21 Legido-Quigley H, McKee M. Patients seeking treatment 
abroad. BMJ  2010;341:c5769.
22 European Commission. High level process of reflection 
on patient mobility and healthcare developments in 
the European Union. Health and Consumer Protection 
Directorate-General, 2003.
23 European Commission. High Level Group on Health 
Services and Medical Care, HLG/2004/21 FINAL. 2004.
24 Council of the European Union. Council conclusions on 
common values and principles in European Union Health 
Systems: Official Journal of the European Union C 146/1 
22.6.2006. 2006.
25 European Parliament. European Parliament legislative 
resolution of 23 April 2009 on the proposal for a directive 
of the European Parliament and of the council on the 
application of patients’ rights in cross-border healthcare 
(COM(2008)0414 – C6-0257/2008 – 2008/0142(COD))
(Codecision procedure: first reading). 2009.
26 Council of the European Union. Proposal for a directive 
of the European Parliament and of the council on the 
application of patients’ rights in cross-border healthcare 
(first reading) (LA + S)- Adoption of (a) the Council’s 
position; (b) the statement of the Council’s reasons. 2010.
27 European Parliament. Recommendations for second 
reading on the council position at first reading with a view 
to the adoption of a directive of the European Parliament 
and of the council on the application of patients’ rights in 
cross-border healthcare 11038/2010 – C7 0266/2010 – 
2008/0142(COD)). 2010.
28 Legido-Quigley H, McKee M, Walshe K, Sunol R, Klazinga 
N, Nolte E. How can quality of health care be safeguarded 
across the European Union? BMJ 2008;336:920-3.
29 Busse R, van Ginneken E, Schreyögg J, Velasco Garrido 
M. Benefits Baskets and Tariffs. In: Wismar M, Palm W, 
Figueras J, Ernst K, van Ginneken E, eds. Cross-border 
healthcare in the EU: mapping and analysing practices 
and policies. European Observatory on Health Systems 
and Policies, 2011.
30 Bhalla A, Tilling K, Kolominsky-Rabas P, Heuschmann 
P, Megherbi SE, Czlonkowska A, et al. Variation in the 
management of acute physiological parameters after 
ischaemic stroke: a European perspective. Eur J Neurol 
2003;10:25-33.
31 European Parliament. News: cross-border health care—
Françoise Grossetête MEP explains ahead of vote Public 
health. 2010.
32 European Parliament. Amendments by the European 
Parliament to the council position at first reading with 
a view to the adoption of a directive of the European 
Parliament and of the council on the application 
of patients’ rights in cross-border healthcare 
(11038/2/2010 - C7-0266/2010 - 2008/0142(COD)). 
2011.
33 Wismar M, Palm W, Figueras J, Ernst K, van Ginneken E. 
Cross-border healthcare in the EU: mapping and analysing 
practices and policies. European Observatory on Health 
Systems and Policies, 2011.
34 Rosenmöller M, McKee M, Baeten R. Patient mobility in 
the European Union: learning from experience. European 
Observatory on Health Systems and Policies, 2006.
35 Council of the European Union. Council adopts its position 
on patient’s rights in cross-border healthcare. 13535/10, 
PRESSE 239 2010. 2010.
Cite this as: BMJ 2011;342:d296
 ЖDiscuss cross-border 
healthcare on doc2doc, 
BMJ Group’s global online 
clinical community, at 
http://bit.ly/dM8GiG
